BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Purchased by Vanguard Group Inc.

Vanguard Group Inc. raised its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 2.0% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 15,392,319 shares of the biotechnology company's stock after buying an additional 302,270 shares during the quarter. Vanguard Group Inc. owned about 7.52% of BioCryst Pharmaceuticals worth $108,978,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Point72 Asset Management L.P. lifted its position in shares of BioCryst Pharmaceuticals by 7,385.4% in the second quarter. Point72 Asset Management L.P. now owns 4,004,700 shares of the biotechnology company's stock worth $28,193,000 after buying an additional 3,951,200 shares in the last quarter. State Street Corp lifted its holdings in shares of BioCryst Pharmaceuticals by 47.5% during the 2nd quarter. State Street Corp now owns 11,004,803 shares of the biotechnology company's stock valued at $116,431,000 after purchasing an additional 3,542,051 shares during the last quarter. Braidwell LP lifted its holdings in shares of BioCryst Pharmaceuticals by 92.1% during the 3rd quarter. Braidwell LP now owns 5,362,980 shares of the biotechnology company's stock valued at $37,970,000 after purchasing an additional 2,571,100 shares during the last quarter. Deerfield Management Company L.P. Series C lifted its holdings in shares of BioCryst Pharmaceuticals by 148.6% during the 3rd quarter. Deerfield Management Company L.P. Series C now owns 3,286,000 shares of the biotechnology company's stock valued at $23,265,000 after purchasing an additional 1,964,000 shares during the last quarter. Finally, Millennium Management LLC lifted its holdings in shares of BioCryst Pharmaceuticals by 3,445.8% during the 2nd quarter. Millennium Management LLC now owns 1,948,595 shares of the biotechnology company's stock valued at $20,616,000 after purchasing an additional 1,893,640 shares during the last quarter. Hedge funds and other institutional investors own 85.88% of the company's stock.

BioCryst Pharmaceuticals Price Performance

BCRX stock traded down $0.13 during trading on Thursday, hitting $4.60. The stock had a trading volume of 2,736,190 shares, compared to its average volume of 3,365,577. BioCryst Pharmaceuticals, Inc. has a twelve month low of $4.58 and a twelve month high of $9.06. The stock has a market capitalization of $948.29 million, a P/E ratio of -3.90 and a beta of 1.90. The company's 50-day moving average price is $5.37 and its two-hundred day moving average price is $5.80.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its quarterly earnings data on Monday, February 26th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.04). The firm had revenue of $93.40 million during the quarter, compared to analyst estimates of $89.19 million. As a group, sell-side analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.62 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC reiterated a "buy" rating and set a $12.00 price objective on shares of BioCryst Pharmaceuticals in a report on Monday, January 8th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat.com, BioCryst Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $13.29.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.